Home/Database/MOTS-c
MetabolicClinical Trials

MOTS-c

Mitochondrial Open Reading Frame of the 12S rRNA-c

16 Amino Acids · MW: 2,174.67 Da

Ask AI About This

Amino Acids

16

Molecular Weight

2,174.67 Da

Half-life

~hours (exact unknown)

Research Score

4.3

Studies

67

Storage

N/A

What is MOTS-c?

MOTS-c is a mitochondrial-derived peptide that regulates metabolic homeostasis and exercise physiology. It activates AMPK, improves insulin sensitivity, and mimics the metabolic effects of exercise. Discovered at USC, it represents a new class of mitochondrial signaling peptides.

Key Benefits & Mechanisms

Activates AMPK pathway (exercise mimetic)

Improves insulin sensitivity

Enhances fatty acid oxidation

Prevents diet-induced obesity

Improves exercise capacity

Anti-aging metabolic effects

Cellular stress resistance

Research Summary

MOTS-c is one of the most exciting recent peptide discoveries. Pre-clinical data strongly supports metabolic benefits. First human clinical trial completed at USC showing improved glucose metabolism. Represents a new paradigm of mitochondrial-derived peptide signaling.

Related Peptides

Semaglutide

GLP-1 Receptor Agonist

Semaglutide is a GLP-1 receptor agonist with proven efficacy for weight management and glycemic control. FDA-approved as Ozempic (diabetes) and Wegovy (weight management), it mimics the incretin hormone GLP-1 to regulate appetite and blood sugar.

Metabolic

Tirzepatide

GIP/GLP-1 Dual Receptor Agonist

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It offers superior weight loss compared to GLP-1-only agonists by targeting two incretin pathways simultaneously.

Metabolic

AOD-9604

Anti-Obesity Drug (Modified GH Fragment)

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 177-191) specifically designed for fat metabolism. It stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, making it a targeted fat-loss peptide without typical GH side effects.

Metabolic

Tesamorelin

Synthetic Growth Hormone Releasing Hormone

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved as Egrifta for HIV-associated lipodystrophy, it reduces visceral adipose tissue while maintaining peripheral fat and improving body composition. Produces physiological GH release.

Metabolic